- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04441385
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19). (MARACOVID)
Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (COVID-19), to prevent disease progression to severe Acute Respiratory Distress Syndrome (ARDS).
Patients will be randomized to receive maraviroc (300 mg BID for 14 days) plus standard treatment, or standard treatment alone.
200 subjects will be enrolled and randomized 1:1 in this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08036
- Hospital Clínic
-
Madrid, Spain, 28031
- Hospital Universitario Infanta Leonor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Male or female adult ≥ 18 years of age at the time of giving informed consent.
- 2. Subject is hospitalized.
- 3. SARS-CoV-2 infection confirmed by PCR or other commercial or public health tests, in any biological sample obtained up to 4 days prior to randomization, or that meets locally accepted criteria for clinical diagnosis of COVID-19.
4. Lung involvement confirmed by at least one of the following criteria:
- Radiological infiltrates on imaging test (conventional radiography, computed tomography (CT) or other)
- In the absence of radiological infiltrates, an SpO2 < 95% without oxygen supporting therapy (breathing ambient air), combined with cough, crackles on physical exam, or an LDH > 300 U/L with no other cause.
- 5. Symptom onset ≤ 8 days prior to randomization.
- 6. Understands and agrees to comply with planned study procedures.
- 7. Women of childbearing potential must have a negative test for pregnancy (blood or urine) before their inclusion and agree to use an accepted method of contraception for the duration of the study.
- 8. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.
Exclusion Criteria:
- 1. SpO2 ≤ 91% breathing ambient air and SpO2 < 95% with oxygen in nasal cannula at 2 lpm.
- 2. Patient's attending physician considers the study is not the best medical option, or follow-up after discharge will be difficult.
- 3. A patient who, in the investigator's opinion, is unlikely to survive > 48 hours from inclusion in the study.
- 4. Patients with severe chronic kidney disease (ClCr < 30 ml/min/1.73 m2 or receiving renal replacement therapy in any of its modalities).
- 5. Severe liver disease (Child-Pugh C, ALT > 5 times above upper limit of normal (LSN).
- 6. COPD with FEV1 < 70.
- 7. Known active neoplasia.
- 8. HIV infection. Patients with known HIV infection, under follow-up, and immunovirological stability (CD4> 500 and undetectable viral load) for at least 6 months before inclusion in this study may be included.
- 9. Hemoglobin < 9 gr/dL.
- 10. Prolonged QT, defined as a QT interval > 460 ms. (or > 450 ms. in case of family history of sudden death or long QT syndrome or personal history of repeat syncope without an etiological diagnosis). This criterion will only apply if the standard treatment contains drugs with an effect on the duration (prolongation) of the QT interval.
11.Significant cardiovascular disease, including:
- History of acute myocardial infarction, acute coronary syndrome (unstable angina, coronary by-pass surgery, angioplasty, or coronary stenting) ≤ 6 months prior to randomization
- Symptomatic heart failure (NYHA grade 2 or more) history, or current evidence of cardiac arrhythmia (except atrial fibrillation or flutter and paroxysmal supraventricular tachycardia) and/or conduction abnormalities (excluding branch blocks or Wenckebach grade I and II atrioventricular blocks).
- 12. Known or suspected active autoimmune disease
- 13. Pregnancy or breastfeeding, or positive pregnancy test at baseline or screening visit
- 14. Patients who are expected to be transferred to another facility sooner than 72 hours after inclusion in the study.
- 15. Patients who have received experimental treatment (off-label, compassionate use, or in clinical trials) within 30 days prior to the screening visit, except for treatment considered standard initiated on admission to hospital, up to 48 hours before inclusion in the study.
- 16. Patients who have a history of allergic reactions to maraviroc or any of its components.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test arm
100 subjects will be randomly assigned to this arm.
Patients in the test group will receive 300 mg of maraviroc BID for 14 days (added to standard care).
|
Patients will receive maraviroc 300 mg twice daily for 14 days
Other Names:
|
Other: Control arm
100 subjects will be randomized in this arm and will be treated according to the standard care.
The Ministry of Health has issued detailed guidelines for the management of COVID-19.
Local Institutional Guidelines and Protocols for supportive management will also be implemented.
|
Subjects randomized to control group will be on standard care treatment according to the Ministry of Health and Local Guidelines and Protocols.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients developing severe ARDS.
Time Frame: 28 days
|
A patient with a saturation of 90% or less despite the use of a reservoir mask without rebreathing with a flow of 7 liters per minute (FiO2 0.6 or higher), will be considered to have severe ARDS.
These oximetric criteria have a close correlation with a PaO2 / FiO2 of 100 or less, which defines severe ARDS.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality.
Time Frame: 28 days
|
28 days
|
|
Percentage of patients requiring tracheal intubation, use of Non-invasive Ventilation NIV or High Flow Nasal Cannula (HFNC) devices during the study period
Time Frame: 28 days
|
28 days
|
|
Percentage of patients who progress to severe ARDS, death or ICU admission.
Time Frame: 28 days
|
28 days
|
|
Differences in Time to Clinical Improvement
Time Frame: 28 days
|
Defined as the time (in hours) from the start of the treatment under study to the normalization of temperature, normalization of respiratory rate and SpO2.
|
28 days
|
Change in clinical status of subject on a 7-point ordinal scale.
Time Frame: 28 days
|
The ordinal scale of 7 categories of patient health status ranges from:
|
28 days
|
Percentage of patients requiring immunosuppressive/immunomodulatory treatment as a rescue medication.
Time Frame: 28 days
|
28 days
|
|
Proportion of patients developing adverse effects, serious adverse reactions, laboratory or physical examination findings, EKG abnormalities acquired during the trial, death and adverse events leading to early discontinuation of treatment.
Time Frame: 28 days
|
Classification according to the WHO toxicity scale
|
28 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Víctor Domínguez, MD, Hospital Universitario Infanta Leonor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Fusion Inhibitors
- Viral Fusion Protein Inhibitors
- CCR5 Receptor Antagonists
- Maraviroc
Other Study ID Numbers
- MARACOVID
- 2020-002011-21 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Maraviroc 300 mg
-
Abramson Cancer Center of the University of PennsylvaniaCompletedHematopoietic Stem Cell Transplantation | Graft-versus-host Disease
-
University of California, Los AngelesTerminated
-
University Of PerugiaCompletedInflammation | Atherosclerosis | Cardiovascular Risk Factor | HIV Infection With Other ConditionsItaly
-
Tel-Aviv Sourasky Medical CenterCompleted
-
International Partnership for Microbicides, Inc.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...Completed
-
Bausch Health Americas, Inc.CompletedRheumatoid ArthritisUnited States
-
Novartis PharmaceuticalsCompletedChronic Plaque PsoriasisUnited States
-
Radboud University Medical CenterUnknownAcute Kidney Injury | Critically Ill ChildrenNetherlands
-
King Abdullah International Medical Research CenterNovartisTerminatedMyeloid Leukemia, ChronicSaudi Arabia
-
University of Turin, ItalyWithdrawn